This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic viral infections, and next-generation immune-cell platforms. It highlights promising engineering advances, including universal CAR-T cells, in vivo delivery, CAR-NK cells, and safety switches, while emphasizing unresolved challenges in durability, safety, scalability, and global access.